Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis
Rapid Communications in Mass Spectrometry · 15.12.2026 · 40 (23)
DOI: 10.1002/rcm.70179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, online erschienen am 15.09.2026. Verfasst von Gabriel Reis Alves Carneiro und 6 weiteren Autor:innen. Beteiligte Einrichtung: LBCD, LADETEC, Instituto de Química, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Doping in Sports, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Financiadora de Estudos e Projetos.
Abstract (Originalsprache)
Rationale
Retatrutide (LY3437943) is a novel long‐acting triple incretin receptor agonist that targets the glucagon‐like peptide‐1 receptor (GLP‐1R), glucose‐dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Its pronounced effects on body composition and metabolic health, combined with increasing off‐label use among physically active populations, raise concerns about potential misuse in sport. Despite growing clinical interest and anecdotal reports about use among amateur athletes, information on the detection and elimination profile of retatrutide in humans remains unexplored.
Methods
A method based on liquid chromatography–high‐resolution mass spectrometry (LC‐HRMS) dedicated to monitor retatrutide was developed and validated in human plasma and urine in accordance with World Anti‐Doping Agency (WADA) criteria. Detection was based on the [M + 3H] 3+ precursor ion by targeted selected‐ion monitoring (t‐SIM), with confirmatory analysis via parallel reaction monitoring (PRM) of structurally diagnostic fragment ions. From four retatrutide users who self‐administered 2 mg subcutaneously on Days 1 and 7, blood and urine samples were collected at predefined time points following self‐administration.
Results
The method was proved fit‐for‐purpose regarding selectivity, reliability, robustness, and stability. Limits of detection (LOD) were evaluated using both empirical ≥ 95% detection rate criteria and sigmoidal logistic regression modeling, yielding 6.14 ng/mL in plasma and 2.44 ng/mL in urine. Neither intact retatrutide nor metabolite‐derived signals were detected in urine samples throughout the entire collection period, despite systematic application of multiple extraction strategies. Plasma concentration–time profiles exhibited nonmonotonic behavior, consistent with prolonged subcutaneous absorption and depot‐like release kinetics following repeated dosing.
Conclusion
These findings suggest that plasma represents the appropriate matrix for intact retatrutide detection compared with urine. The extended plasma detection window, approximately 56 days after the first dose, supports plasma‐based testing as a suitable analytical strategy for this and related long‐acting therapeutic peptides in antidoping testing context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LBCD, LADETEC, Instituto de Química, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
- LABPROT, LADETEC, Instituto de Química, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Gabriel Reis Alves Carneiro, Gustavo Ramalho Dos Santos Cardoso, Monica Costa Padilha, Fábio César Sousa Nogueira, Henrique Marcelo Gualberto Pereira
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Financiadora de Estudos e Projetos
Zitieren
APA
Carneiro, G. R. A., da Costa Nunes, I. K., Dos Santos Cardoso, G. R., Dos Santos, P. F., Padilha, M. C., Nogueira, F. C. S., & Pereira, H. M. G. (2026). Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis. Rapid Communications in Mass Spectrometry, 40(23). https://doi.org/10.1002/rcm.70179
Vancouver
Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, et al. Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis. Rapid Communications in Mass Spectrometry. 2026;40(23). doi:10.1002/rcm.70179
BibTeX
@article{Carneiro2026,
author = {Carneiro, Gabriel Reis Alves and da Costa Nunes, Isabelle Karine and Dos Santos Cardoso, Gustavo Ramalho and Dos Santos, Paola Façanha and Padilha, Monica Costa and Nogueira, Fábio César Sousa and Pereira, Henrique Marcelo Gualberto},
title = {Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis},
journal = {Rapid Communications in Mass Spectrometry},
year = {2026},
volume = {40},
number = {23},
doi = {10.1002/rcm.70179}
}
EUVIMED